VEGFA and cardiovascular disorder: If this gene therapy would reach the clinical stage, assessment of VEGFA methylation in fetal cells derived from the maternal blood might be used to identify fetuses that could potentially benefit from placenta-directed gene therapy such as adenovirus vectors containing VEGFA. Again, the altered methylation status of VEGFA is the set-point of methylation throughout life which might predispose to the development of cardiovascular disease.